Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1997-10-09
2000-01-11
Eisenschenk, Chris
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241991, 4242041, 4241851, 424489, 424450, 4353201, 435326, 4352351, 436829, 514 44, 536 2372, A61K 3912, A61K 9127, C12N 1500, C07H 2104
Patent
active
060132582
ABSTRACT:
The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.
REFERENCES:
patent: 4741872 (1988-05-01), DeLuca et al.
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5413797 (1995-05-01), Khan et al.
patent: 5547846 (1996-08-01), Bartsch et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648459 (1997-07-01), Cole et al.
patent: 5656297 (1997-08-01), Bernstein et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5695770 (1997-12-01), Raychaudhuri et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705151 (1998-01-01), Dow et al.
patent: 5709860 (1998-01-01), Raychaudhuri et al.
patent: 5783567 (1998-07-01), Hedley et al.
Jochmus et al., "Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide," The Journal of General Virology, 78:1689-1695, 1997.
Kadish et al., "Cell-mediated immune respones to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific," The Journal of General Virology, 75:2277-2284, 1994.
Kadish et al., "Lymphoproliferative Responses to Human Papillomavirus (HPV) Type 16 Proteins E6 and E7: Outcome of HPV Infection and Associated Neoplasia," Journal of the National Cancer Institute, 89:1285, 1997.
Kast et al., "Human Leukocyte Antigen-A2.1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Indentified by Using the Processing-Defective Human Cell Line T2," The Journal of Immunotherapy, 14:115-120, 1993.
Collins et al., "Processing of Exogenous Liposome-Encapsulated Antigens In Vivo Generates Class I MHC-restricted T Cell Responses," The Journal of Immunology, 148:3336-3341, No. 11, Jun. 1, 1992.
Donnelly et al., "Immunization with DNA," Journal of Immunological Methods, 176:145-152, No. 2, 1994.
Elliott et al., "Processing of Major Histocompatibility Class I-restricted Antigens in the Endoplasmic Reticulum," The Journal of Experimental Medicine, 181:1481-1491, Apr. 1995.
Fries et al., "Liposomal Malaria Vaccine in Humans: A Safe and Potent Adjuvant Strategy," Proceedings of the National Academy of Sciences, 89:358-362, Jan. 1992.
Fynan et al., "DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations," Proceedings of the National Academy of Sciences, 90:11478-11482, 1993.
Hurtenbach et al., "Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatibility Complex-blocking Peptide," The Journal of Experimental Medicine, 177:1499-1504, 1993.
Madden et al., "The Antigenic Indentity of Peptide-MHC Complexes: A Comparison of the Conformations of Five Viral Peptides Presented by HLA-A2," Cell, 75:693-708, Nov. 19, 1993.
Mowat et al., "ISCOMS--A Novel Strategy for Mucosal Immunization?", Immunology Today, 12:383-385, 1991.
Nabel et al., "Transduction of a Foreign Histocompatibility Gene into the Arterial Wall Induces Vasculitis," Proceedings of the National Academy of Sciences, 89:5157-5161, No. 11, Jun. 1992.
Osband et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," Immunology Today, 11:193-195, 1990.
Reddy et al., "In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes," The Journal of Immunology, 148:1585-1589, No. 5, Mar. 1, 1992.
Ressing et al., "Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A 0201-restricted E7-encoded Epitope," Cancer Research, 56:582-588, Feb. 1, 1996.
Ressing et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Indentified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A 0201 Binding Peptides," The Journal of Immunology, 154:5934-5943, Jun. 1, 1995.
Shrine et al., "Pangaea Aims Naturally Processed Peptides at First Viral Target: Human Papilloma Virus," BioWorld Today, The Biotechnology Newspaper, 7:1-2, May 15, 1996.
Stellar et al., "Human Papillomavirus Immunology and Vaccine Prospects," Journal of the National Cancer Institute Monographs, No. 21, 1996, pp. 145-148.
Takahashi et al., "Induction of CD8 Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," Nature, 344:873-875, Apr. 1990.
Tsukui et al., "Interleukin 2 Production In Vitro by Peripheral Lymphocytes in Response to Human Papillomavirus-derived Peptides: Correlation with Cervical Pathology," Cancer Research, 56:3855-4085, 1996.
Urban et al., "A Subset of HLA-B27 Molecules Contains Peptides Much Longer Than Nonamers," Proceedings of the National Academy of Sciences, 91:1534-1538, Feb. 1994.
Vitiello et al., "Development of a Lipopeptide Based Therapeutic Vaccine to Treat Chronic HBV Infection," The Journal of Clinical Investigation, 95:341-349, Jan. 1995.
Vitiello et al., "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," J. Exp. Med., 173:1007-1015, Apr. 1991.
Feltkamp et al., "Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells," European Journal of Immunology, 23:2242-2249, 1993.
Gao et al., "Tumor-Associated E6 Protein of Human Papillomavirus Type 16 Contains an Ususual H-2K.sup.b -Restricted Cytotoxic T Cell Epitope," The Journal of Immunology, 155:5519-5526, 1995.
Kast et al., "Role of HLA-A Motifs in Indentification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," The Journal of Immunology, 152:3904-3912, 1994.
Lin et al., "Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen," Cancer Research, 56:21-26, 1996.
Tarpey et al., "Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif," Immunology, 81:222-227, 1994.
Zhu et al., "Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H-2.sup.d Mice," Scandinavian Journal of Immunology, 42:557-563, 1995.
Chicz Roman M.
Collins Edward J.
Hedley Mary Lynne
Urban Robert G.
Eisenschenk Chris
Salimi Ali R.
Zycos Inc.
LandOfFree
Immunogenic peptides from the HPV E7 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides from the HPV E7 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides from the HPV E7 protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459839